Targeting Inhibition of Fibroblast Activation Protein-α and Prolyl Oligopeptidase Activities on Cells Common to Metastatic Tumor Microenvironments

被引:42
|
作者
Christiansen, Victoria J.
Jackson, Kenneth W.
Lee, Kyung N.
Downs, Tamyra D.
McKee, Patrick A.
机构
[1] Univ Oklahoma, Coll Med, William K Warren Med Res Ctr, Oklahoma City, OK 73190 USA
[2] Univ Oklahoma, Coll Med, Dept Med, Oklahoma City, OK 73190 USA
来源
NEOPLASIA | 2013年 / 15卷 / 04期
基金
美国国家卫生研究院;
关键词
POTENTIAL THERAPEUTIC TARGET; ANTIPLASMIN-CLEAVING ENZYME; MESENCHYMAL STEM-CELLS; SERINE-PROTEASE; HUMAN BONE; DIPEPTIDYLPEPTIDASE-IV; STROMAL FIBROBLASTS; MOLECULAR-CLONING; EXPRESSION; OVEREXPRESSION;
D O I
10.1593/neo.121850
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fibroblast activation protein (FAP), a membrane prolyl-specific proteinase with both dipeptidase and endopeptidase activities, is overexpressed by reactive stromal fibroblasts during epithelial-derived cancer growth. FAP digests extracellular matrix as tissue is remodeled during cancer expansion and may also promote an immuno-tolerant tumor microenvironment. Recent studies suggest that nonspecific FAP inhibitors suppress human cancer xenografts in mouse models. Prolyl oligopeptidase ( POP), another prolyl-specific serine proteinase, is also elevated in many cancers and may have a regulatory role in angiogenesis promotion. FAP and POP cell-associated activities may be targets for diagnosis and treatment of various cancers, but their accessibilities to highly effective specific inhibitors have not been shown for cells important to cancer growth. Despite their frequent simultaneous expression in many cancers and their overlapping activities toward commonly used substrates, precise, separate measurement of FAP or POP activity has largely been ignored. To distinguish each of the two activities, we synthesized highly specific substrates and inhibitors for FAP or POP based on amino acid sequences surrounding the scissile bonds of their respective putative substrates. We found varying amounts of FAP and POP protein and activities on activated fibroblasts, mesenchymal cells, normal breast cells, and one breast cancer cell line, with some cells exhibiting more POP than FAP activity. Replicating endothelial cells (ECs) expressed POP but not FAP until tubulogenesis began. Targeting FAP-positive cells, especially mesenchymal stem cells and cancer-associated fibroblasts for inactivation or destruction, and inhibiting POP-producing EC may abrogate stromal invasion and angiogenesis simultaneously and thereby diminish cancer growth.
引用
收藏
页码:348 / 358
页数:11
相关论文
共 50 条
  • [31] Theranostics in targeting fibroblast activation protein bearing cells: Progress and challenges
    Rezaei, Sahar
    Gharapapagh, Esmaeil
    Dabiri, Shahram
    Heidari, Pedram
    Aghanejad, Ayuob
    LIFE SCIENCES, 2023, 329
  • [32] Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts
    Lee, J
    Fassnacht, M
    Nair, S
    Boczkowski, D
    Gilboa, E
    CANCER RESEARCH, 2005, 65 (23) : 11156 - 11163
  • [33] Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells
    Baum, Patrick
    Mueller, Dafne
    Rueger, Ronny
    Kontermann, Roland E.
    JOURNAL OF DRUG TARGETING, 2007, 15 (06) : 399 - 406
  • [34] Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy
    Hamson, Elizabeth J.
    Keane, Fiona M.
    Tholen, Stefan
    Schilling, Oliver
    Gorrell, Mark D.
    PROTEOMICS CLINICAL APPLICATIONS, 2014, 8 (5-6) : 454 - 463
  • [35] Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes
    Tansi, Felista L.
    Rueger, Ronny
    Kollmeier, Ansgar M.
    Rabenhold, Markus
    Steiniger, Frank
    Kontermann, Roland E.
    Teichgraeber, Ulf K.
    Fahr, Alfred
    Hilger, Ingrid
    PHARMACEUTICS, 2020, 12 (04)
  • [36] Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy
    Liu, Yu
    Tang, Haocheng
    Song, Tianchi
    Xu, Mengxin
    Chen, Junyi
    Cui, Xi-Yang
    Han, Yuxiang
    Li, Zhu
    Liu, Zhibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (09) : 2636 - 2646
  • [37] Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas
    Mersmann, M
    Schmidt, A
    Rippmann, JF
    Wüest, T
    Brocks, B
    Rettig, WJ
    Garin-Chesa, P
    Pfizenmaier, K
    Moosmayer, D
    INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (02) : 240 - 248
  • [38] Organotrifluoroborate Enhances Tumor Targeting of Fibroblast Activation Protein Inhibitors for Targeted Radionuclide Therapy
    Liu, Y.
    Xu, M.
    Chen, J.
    Cui, X.
    Liu, Z.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S763 - S764
  • [39] Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy
    Yu Liu
    Haocheng Tang
    Tianchi Song
    Mengxin Xu
    Junyi Chen
    Xi-Yang Cui
    Yuxiang Han
    Zhu Li
    Zhibo Liu
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2636 - 2646
  • [40] Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton
    Barkan, Dalit
    Kleinman, Hynda
    Simmons, Justin L.
    Asmussen, Holly
    Kamaraju, Anil K.
    Hoenorhoff, Mark J.
    Liu, Zi-yao
    Costes, Sylvain V.
    Cho, Edward H.
    Lockett, Stephen
    Khanna, Chand
    Chambers, Ann F.
    Green, Jeffrey E.
    CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) : 867 - 867